Almirall stock reports stronger H1 profitability as EADV data emerge

Published on 10/04/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock carries a 25.0 percent H1 2026 EBITDA margin after EBITDA rose 23.7 percent year over year. EADV data showed 92.9 percent EASI-75 responses at week 108.

Isometrische 3D-Illustration einer Pharma-Wertschöpfungskette von Labor bis Lieferwagen — Almirall S.A. (ES0157097017) veranschaulicht isometrisch die Pharma-Wertschöpfungskette von Labor bis Vertrieb detailliert, Illustration mit AI erstellt.

Almirall stock (ISIN ES0157097017) was last at EUR 10.22 on Madrid SIBE on October 2, 2026 at 5:35 p.m. CEST, with a daily change of 0.20 percent. The company paired its H1 2026 financial update with new EADV data on lebrikizumab, giving investors two concrete measures of commercial execution and pipeline support.

Profitability outpaced sales growth

According to Almirall on July 24, 2026, H1 2026 net sales reached EUR 602.7 million, an increase of 7.5 percent from H1 2025. EBITDA rose 23.7 percent to EUR 150.7 million, while the EBITDA margin reached 25.0 percent compared with 21.7 percent a year earlier.

The comparison matters because EBITDA expanded 16.2 percentage points faster than sales growth. Almirall also reiterated full-year 2026 guidance for net sales growth of 9 percent to 12 percent and EBITDA of EUR 270 million to EUR 290 million, keeping the second-half execution in focus.

EADV data strengthen the dermatology case

On October 1, 2026, Almirall reported ADlong results presented at EADV 2026. At week 108, 92.9 percent of patients achieved an EASI-75 response and 73.8 percent achieved EASI-90, while 66.7 percent reached an IGA 0/1 response.

The study enrolled 174 patients and covered 108 weeks of treatment, with exposure extending to five years across the development program. The safety readout included a 2.9 percent discontinuation rate from treatment-emergent adverse events and a 5.7 percent rate of serious treatment-emergent adverse events.

Stock remains below its yearly high

Almirall stock was last at EUR 10.22 on Madrid SIBE on October 2, 2026, with a 52-week range of EUR 10.02 to EUR 13.98. Its market capitalization was EUR 2.2 billion and volume reached 99,158 shares on the same date.

The investor calendar lists November 9, 2026, for Almirall's 9M 2026 financial results. That report should provide the next quantified test of whether the 25.0 percent H1 EBITDA margin and the reiterated full-year range are carrying into the second half.